Oramed Pharmaceuticals (ORMP) Free Cash Flow (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Free Cash Flow came in at -$2.9 million in Q1 2026, up 17.09% YoY from -$2.5 million in Q1 2025, and down 523.93% on a QoQ basis from -$468000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Free Cash Flow (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Free Cash Flow data on file, last reported at -$2.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 17.09% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.6 million (up 18.35% YoY) and the FY2025 annual result came in at -$9.2 million, down 8.59% from the prior year.
- Free Cash Flow eased to -$2.9 million in Q1 2026, from -$468000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $2.1 million in Q2 2024 to a low of -$9.2 million in Q1 2022.
- A 5-year average of -$3.5 million and a median of -$2.7 million in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 178.22% in 2024, down 878.79% in 2024.
- Tracing ORMP's Free Cash Flow over 5 years: stood at -$8.4 million in 2022, then surged by 83.02% to -$1.4 million in 2023, then tumbled by 35.26% to -$1.9 million in 2024, then soared by 75.65% to -$468000.0 in 2025, then plunged by 523.93% to -$2.9 million in 2026.
- The last three Free Cash Flow figures came in at -$2.9 million (Q1 2026), -$468000.0 (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | -202,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -202,000.00 |
| Jun 30, 2026 | -202,000.00 |
| Mar 31, 2026 | -2.92 Mn |
| Mar 31, 2026 | -2.92 Mn |
| Dec 31, 2025 | -468,000.00 |
| Dec 31, 2025 | -468,000.00 |
| Sep 30, 2025 | -1.63 Mn |
| Sep 30, 2025 | -1.63 Mn |
| Jun 30, 2025 | -3.54 Mn |
| Jun 30, 2025 | -3.54 Mn |
| Mar 31, 2025 | -3.52 Mn |
| Mar 31, 2025 | -3.52 Mn |
| Dec 31, 2024 | -1.92 Mn |
| Dec 31, 2024 | -1.92 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | -1.48 Mn |
| Mar 31, 2024 | -1.48 Mn |